Sodium Sulfacetamide, Sulfur
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Sodium Sulfacetamide, Sulfur
- Generic name
- SULFACETAMIDE SODIUM, SULFUR
- Manufacturer
- BioComp Pharma, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 99e52390-478e-49ed-87de-aa794379bfeb
- SPL ID
- f798f8d7-639f-2a12-e053-6294a90a00fb
- Version
- 5
- Effective date
- 2023-08-24
- Source export date
- 2026-10-12
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/edd23646015c9adc800cdbe2b778398a2d2b70e90dce5721ef2b191499a0397f/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 02:51:51
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Sodium Sulfacetamide, Sulfur | openfda.brand_name | |
| generic name | SULFACETAMIDE SODIUM, SULFUR | openfda.generic_name | |
| manufacturer name | BioComp Pharma, Inc. | openfda.manufacturer_name | |
| ndc | package | 44523-550-08 | openfda.package_ndc |
| ndc | product | 44523-550 | openfda.product_ndc |
| ndc11 | package | 44523055008 | derived:openfda.package_ndc |
| rxcui | 1000895 | openfda.rxcui | |
| spl id | f798f8d7-639f-2a12-e053-6294a90a00fb | id | |
| spl set id | 99e52390-478e-49ed-87de-aa794379bfeb | set_id | |
| unii | 4NRT660KJQ | openfda.unii | |
| unii | 70FD1KFU70 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF THE REACH OF CHILDREN.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.